Notre science

Posters & Publications

2019

Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular dystrophy. Latil et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

 

In vivo effects of Sarconeos (API BIO101) on mouse model of severe spinal muscular atrophy. Belzier et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

 

In MYODA clinical program: A new approach unraveling drug effects through a composite outcome score encompassing ambulant to non-ambulant disease stages. Chabane et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

 

The MYODA seamless clinical trial design: a true innovation for rare diseases including DMD. Chabane et al. Poster presentation at the 6th Annual International Congress of Myology, March 25-28, 2019, Bordeaux, France.

 

SARCONEOS (API BIO101) targets Mas receptor within the protective arm of the renin angiotensin system and proves efficacy in various models of muscle wasting. Dilda et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

Abstract in press in The Journal of Frailty & Aging.

 

Evaluation of safety and efficacy of BIO101, a new investigational drug for Sarcopenia: a double-blind, placebo controlled, randomized clinical trial. Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.

Abstract in press in The Journal of Frailty & Aging.

 

Designing a clinical program for BIO101, a Mas receptor activator to target Age-related sarcopenia. Dioh et al. Oral presentation at 10th International Conference on Frailty & Sarcopenia Research (ICFSR), February 20-22, 2019, Miami, USA.